BAGSVÆRD, Denmark, Nov. 6, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated the...
Each year, Australian organisations spend billions of dollars running conferences, exhibitions, incentive programs, roadsho...
KPMG remains a case study in how not to action Crisis Comms. A crisis at this magnitude affects a global audience and kno...
Every four years, the FIFA World Cup becomes one of the largest commercial events on Earth. Billions of people watch match...
Australian student fintech MIST has secured a $3.5 million investment from DoxAI, providing fresh ...
In response to Tasmania’s growing mental health crisis, a new purpose-built, multi-disciplinary me...
Preparing meals at home is one of life's pleasures, but even the cleanest kitchens can become a so...
The Korea Tourism Organization (KTO) has launched Korea Unlocks More of You, a new national campai...
Preparing meals at home is one of life's pleasures, but even the cleanest kitchens can become a so...
Launceston will once again become a platform for bold art, performance, music and shared experienc...
Because a protein hit shouldn’t mean a flavour trade-off.Wellbeing has become the defining obsession...